Background and aims
Current international guidelines on inflammatory bowel disease (IBD) advise to continue immunomodulating medication during pregnancy. Data on the effect of this medication on maternal Tdap (Tetanus-Diphtheria-acellular pertussis) vaccination and transfer of antibodies to the infant are scarce.
Methods
Pregnant women with IBD receiving various immunomodulating medications and their infants were prospectively recruited in the Pregnancy Exposure to TNF alpha inhibitors and Immunological effect (PETIT) study cohort from 16 hospitals in the Netherlands between December 2018 and March 2023. All women were offered maternal Tdap vaccination according to the Dutch National Immunization Program. IgG concentrations against all Tdap components were measured at birth (maternal and cord blood) and at 2 months of age in the infant, preceding active immunization. We compared geometrical mean concentrations (GMCs) in IBD mother-infant pairs with healthy control mother-infant pairs.
Results
Geometrical mean concentrations of antibodies against all Tdap components were significantly higher in 135 maternally vaccinated mothers and their infants compared with 25 unvaccinated IBD women-infant pairs treated with immunomodulating medication during pregnancy, at all timepoints. However, GMC against pertactin (PRN) was significantly lower in vaccinated IBD mother-infant pairs compared to healthy vaccinated control mother-infant pairs, particularly in mothers treated with anti-tumor necrosis factor alpha and their infants.
Conclusions
Maternal Tdap vaccination in women with IBD receiving immunomodulating medication during pregnancy results in significantly higher Tdap-antibody concentrations in their infants compared to infants of unvaccinated IBD mothers, although GMC was lower for PRN compared to healthy controls. These results support current recommendations to advise maternal Tdap vaccination in pregnant women receiving immunomodulating medication.
© The Author(s) 2025. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Overview publication
| Title | Impact of immunomodulating medication on maternal Tdap vaccination-induced antibodies in infants. |
| Date | June 4th, 2025 |
| Issue name | Journal of Crohn's & colitis |
| Issue number | v19.6 |
| DOI | 10.1093/ecco-jcc/jjaf090 |
| PubMed | 40452230 |
| Authors | |
| Info | PETIT study, van Achterberg H, van den Akker ESA, van den Akker T, van Beek RHT, van den Berg-Zuiddam D, Bloemenkamp KWM, van Dalen-Vink IH, Demmers J, Dijkman A, Dik WA, Dubbink-Verheij GH, van Dunné FM, van Eijk R, Esser ME, Ganzevoort W, El Ghabzouri H, de Haan-Jibbink JM, Hajenius PJ, van Houten MA, de Jong L, Harzing B, Hermes W, Heuts-van de Kragt I, Hirdes MMC, van Hoorn ME, Ten Hove CH, Hurkmans P, Kramer M, van Kempen AAMW, van der Marel S, van der Meulen-de Jong AE, Middelhof I, Mulders AGMGJ, Nagtzaam NMA, Nijman RGW, Noordzij JG, Nuis-Vrijhof CAM, van Oirschot CM, van der Plas K, Posthumus-van Sluijs SJ, Reijnen ICGM, van Rhee-Binkhorst JM, Rijntjes-Jacobs EGJ, van Rossem MC, Rövekamp-Abels LW, Sie SD, Simons SHP, Smits GP, Sol JJ, Srivastava N, Stas HG, Stok D, Sturm P, Talhaoui K, Tramper-Stranders GA, van Tweel XW, van Veen M, Veenhof MB, Verheul RJ, Vermeulen MJ, Vermont CL, Versendaal HJ, van Vliet NSM, Vollebregt KC, Vredevoogd CB, van Wering HM, Wijnberger LDE, van Wijngaarden WJ, Wildenbeest JG, Wisse J, Wonders J, van der Woude CJ |
| Keywords | immunomodulating medication, pregnancy, vaccination |
| Read | Read publication |